Collegium Appoints Richard Malamut, M.D., as Chief Medical Officer

Stoughton, Massachusetts, UNITED STATES

STOUGHTON, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced the appointment of Richard Malamut, M.D., as the company’s first Chief Medical Officer, effective April 1, 2019. In this newly created role, Dr. Malamut will lead Collegium’s Clinical, Medical Affairs, Regulatory and Scientific Affairs functions.

“We are excited to have Rick join the Collegium leadership team. He brings with him more than 25 years of experience across all stages of product development, as well as clinical and operational expertise,” said Joe Ciaffoni, Chief Executive Officer of Collegium. “We look forward to his contributions, as we leverage his extensive background in the field of pain medicine to deliver on our commitment to become the leader in responsible pain management.” 

Most recently, Dr. Malamut served as Chief Medical Officer, Head of Research and Development and Senior Vice President for Braeburn Pharmaceuticals, Inc. Prior to that, Dr. Malamut was Chief Medical Officer at Avanir Pharmaceuticals and was Senior Vice President of Global Clinical Development at Teva Pharmaceutical Industries Ltd., where he was responsible for Pain, Neuropsychiatry and repurposing and reformulation of existing molecules. His experience also includes roles of increasing responsibility at Bristol-Myers Squibb and AstraZeneca.

Dr. Malamut earned his medical degree from Hahnemann University in Philadelphia and completed both a residency in neurology and a fellowship in neuromuscular disease. He worked as a board-certified academic and clinical neurologist for 17 years and has more than 50 publications in the fields of pain medicine, neuromuscular disease, autonomic disease and neurodegenerative disease.

“My experience in developing medicines for pain management equip me with a unique perspective to apply to the advancement and expansion of Collegium’s pain portfolio,” said Dr. Malamut. “I am thrilled to be joining a company with a deep commitment to offering differentiated and innovative treatment options for people suffering from pain and look forward to contributing to the success of Collegium.”

About Collegium Pharmaceutical, Inc.

Collegium is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium’s headquarters are located in Stoughton, Massachusetts. For more information, please visit the company’s website at

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. We may, in some cases, use terms such as "predicts,“ “forecasts,” "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including our ability to obtain and maintain regulatory approval of our products and product candidates; our ability to effectively commercialize in-licensed products and manage our relationships with licensors; the success of competing products that are or become available; our ability to obtain reimbursement and third-party payor contracts for our products; the rate and degree of market acceptance of our products and product candidates; the outcome of any patent infringement or other litigation that may be brought by or against us, including litigation with Purdue Pharma, L.P. and Teva Pharmaceuticals USA, Inc.; our ability to secure adequate supplies of active pharmaceutical ingredient for each of our products and product candidates; our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including U.S. Drug Enforcement Agency, or DEA, compliance; and the accuracy of our estimates regarding expenses, revenue, capital requirements and need for additional financing. These and other risks are described under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2018, and in other reports which we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact Data